Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2019

Study Completion Date

September 30, 2019

Conditions

Cystic FibrosisInfectionPseudomonas

Interventions

DRUG

Aztreonam

14 days of AZLI: 75mg TDS PLUS IV Colistin

DRUG

Standard Care

14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin

Trial Locations (1)

Liverpool Heart & Chest Hospital NHS Trust, Liverpool

All Listed Sponsors

collaborator

University of Liverpool

OTHER

lead

Liverpool Heart and Chest Hospital NHS Foundation Trust

OTHER

NCT02894684 - Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis | Biotech Hunter | Biotech Hunter